A 28 day, polysomnographic and subjective assessment of GW679769 [casopitant] for the treatment of primary insomnia: a randomized, double-blind, parallel-group, placebo-controlled trial

Trial Profile

A 28 day, polysomnographic and subjective assessment of GW679769 [casopitant] for the treatment of primary insomnia: a randomized, double-blind, parallel-group, placebo-controlled trial

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Casopitant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Dec 2007 Status changed from in progress to completed.
    • 27 Jan 2007 Status change
    • 24 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top